AlphAIAlphAI — Financial news for AI agents
seekingalpha.com$ETRA

Electra Therapeutics Q3 GAAP EPS of $3.47 beats by $4.44

Electra Therapeutics (ETRA) reported Q3 GAAP EPS of $3.47, exceeding estimates by $4.44. The company's net loss widened to $23.9M from $18.1M year-over-year. R&D expenses increased to $17.3M from $14M.

Original reporting
seekingalpha.com
Published Nov 13, 2026, 12:52 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 12:55 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Electra Therapeutics Q3 GAAP EPS of $3.47 beats by $4.44 — source image
Source · seekingalpha.com
Decision brief

The 30-second read

$ETRABullishHigh
01

Why it matters

The earnings beat provides a fresh catalyst for short-term trading.

02

Market read

Primary earnings disclosure for a listed biotech, offering immediate trading opportunity.

03

What to watch

R&D spend increase may pressure future margins.

Relevance 7/10Novelty 8/10Timing: today

Background

Electra Therapeutics released its Q3 2026 earnings via a press release.

Company-level read

Ticker impact

$ETRABullishHigh confidence
Context

Q3 GAAP EPS of $3.47 beats expectations by $4.44; net loss $23.9M versus $18.1M a year ago.

Expected impact

likely upward pressure as investors price in the earnings beat

Evidence & confidence

The surprise EPS beat and higher loss guidance are fresh data that can move the stock immediately.

Market effects

Sector

May lift sentiment for biotech peers reporting earnings.

Regional

Limited to US biotech sector.

Global

Low

Counterpoint

What could challenge this read

The larger net loss could signal deeper cash burn, tempering upside.

Key entities

  • company
    Electra Therapeutics, Inc.

    Biotech firm reporting Q3 results.

Read at source← All news

StoryElectra Therapeutics posts Q3 2026 loss of $23.9 million and EPS of –$3.47

Also covered by

1 outlet

Related articles

$ETRAMed

Electra Therapeutics Reports Third Quarter 2026 Financial Results and Recent Portfolio

Electra Therapeutics, Inc. (ETRA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Electra Therapeutics Reports Third Quarter 2026 Financial Results and Recent Portfolio Highlights Ipsoprubart Advancing in Global Registrational Program as Potential First Treatment for sHLH Broadly; Enrollment Completion Expected in Second Half of 2027 Ipsoprubart Therapeutic Ex

SEC EDGAR 8-K
$ETRAMed

H.C. Wainwright initiates Electra stock coverage with buy rating

H.C. Wainwright initiated coverage on Electra Therapeutics (ETRA) with a buy rating and $30 price target, citing clinical progress and financial flexibility. The stock trades near its 52-week low at $8.71. Multiple analysts rate ETRA positively, highlighting its lead drug candidate, ipsoprubart, in trials for hemophagocytic lymphohistiocytosis. The company's upcoming IPO is expected to price above its $14-$16 range.

investing.com
$ETRAMed

JPMorgan initiates Electra stock at Overweight on sHLH drug potential

JPMorgan initiated coverage on Electra (NASDAQ:ETRA) with an Overweight rating and a $36.00 price target, implying 300% upside from the current $9.05. The firm's thesis is based on the potential of ipsoprubart, a drug in Phase 2/3 trials for secondary hemophagocytic lymphohistiocytosis (sHLH). Electra is preparing for an IPO priced between $14 and $16, with strong institutional demand.

investing.com